Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road

A sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantati...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 28; no. 19; pp. 4167 - 4170
Main Authors Adrianzen-Herrera, Diego A, Shastri, Aditi
Format Journal Article
LanguageEnglish
Published United States 03.10.2022
Subjects
Acute Disease
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute - mortality
Recurrence
Retrospective Studies
Online AccessGet full text

Cover

More Information
Summary:A sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantation (EBMT) analysis reports substantial posttransplant survival gains for patients with active disease who received transplants. Decreased relapse was the largest contributor to survival, a cause for optimism in this challenging population. See related article by Nagler et al., p. 4258.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-22-1881